128.3 🩺 內科專科考前版

128.3.0.1 1⃣ 22E 曎新

  • mRNA 平台爆癌: COVID-19 證明可行 → RSV (Moderna mRESVIA), flu mRNA (in trials), HIV mRNA (in trials), cancer mRNA vaccine (personalized neoantigen)
  • PCV20 (2021): 取代 PCV13 + PPSV23 in many guidelines
  • Shingrix 取代 Zostavax (live) — recombinant glycoprotein E + AS01 adjuvant; 2 doses; >90% efficacy
  • RSV vaccines (2023): GSK Arexvy, Pfizer Abrysvo, Moderna mRESVIA — for 60+ adults
  • Long-acting mAb passive: nirsevimab (RSV in infants), bebtelovimab (COVID, withdrawn due variant)

128.3.0.2 2⃣ 台灣健保 + 預防醫孞

  • 公費疫苗: 嬰幌兒 schedule, 國䞭女 HPV, 65+ flu/PCV, 50-59 流感補助
  • 自費: shingles, additional HPV doses, RSV, JEV, yellow fever, rabies pre-exposure
  • TVSAP (台灣疫苗安党監枬): adverse event reporting

128.3.0.3 3⃣ Vaccine Hesitancy

  • 台灣 + 党球趚勢
  • 䞻芁原因: 安党顧慮 + 蚊息混亂 + 信任䞍足
  • 對策: educational, transparent communication, IDC 䞻動宣導